Status:
UNKNOWN
Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso
Lead Sponsor:
Gynuity Health Projects
Conditions:
Medical; Abortion, Fetus
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
The goal of this study is to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Burkina Faso.
Eligibility Criteria
Inclusion
- Having an ongoing pregnancy of 13-22 weeks gestation
- Be willing to undergo surgical completion if necessary
- Have no contraindications to study procedures, according to provider
- Be willing and able to consent to participate in the study
- Be willing to follow study procedures
- Respect legal indications for obtaining an abortion
Exclusion
- Known allergy to mifepristone or misoprostol/prostaglandin
- Any contraindications to vaginal delivery, including placenta previa
- Previous transmural uterine incsion
Key Trial Info
Start Date :
May 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03269279
Start Date
May 20 2017
End Date
December 31 2019
Last Update
May 30 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
CHUSS
Bobo-Dioulasso, Burkina Faso
2
CMA Boromo
Boromo, Burkina Faso
3
CHUYO
Ouagadougou, Burkina Faso
4
CHR Ouahigouya
Ouahigouya, Burkina Faso